NASDAQ · AGIO
Healthcare · Biotechnology
$34.90
Up+$1.74 (+4.99%)
Updated Oct 21, 2026, 1:58 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AGIO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 19, 2026
AGIO closed at $34.90 after 20 trading sessions, down 0.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | $31.61 | $35.025 | $31.61 | $34.90 | 1.97M |
| Oct 16, 2026 | $32.35 | $32.515 | $31.16 | $31.32 | 952.68K |
| Oct 15, 2026 | $31.70 | $32.84 | $31.35 | $32.32 | 2.05M |
| Oct 14, 2026 | $30.07 | $31.11 | $29.67 | $30.97 | 930.9K |
| Oct 13, 2026 | $30.60 | $30.99 | $30.095 | $30.21 | 1.17M |
| Oct 12, 2026 | $31.84 | $32.22 | $30.69 | $30.82 | 647.85K |
| Oct 9, 2026 | $31.85 | $32.15 | $31.52 | $31.81 | 835.68K |
| Oct 8, 2026 | $31.46 | $32.315 | $31.16 | $31.92 | 2.08M |
| Oct 7, 2026 | $31.37 | $32.27 | $31.0701 | $31.79 | 1.67M |
| Oct 6, 2026 | $31.49 | $32.03 | $30.79 | $31.72 | 1.28M |
| Oct 5, 2026 | $31.65 | $31.76 | $30.78 | $31.25 | 808.72K |
| Oct 2, 2026 | $32.82 | $32.82 | $31.65 | $31.80 | 569.93K |
| Oct 1, 2026 | $33.25 | $33.73 | $32.424 | $32.48 | 1.7M |
| Sep 30, 2026 | $33.67 | $34.0601 | $33.20 | $33.25 | 1.55M |
| Sep 29, 2026 | $33.21 | $33.545 | $32.695 | $33.30 | 416.41K |
| Sep 28, 2026 | $32.53 | $34.115 | $32.35 | $33.42 | 1.35M |
| Sep 25, 2026 | $32.93 | $33.33 | $32.54 | $32.58 | 996.51K |
| Sep 24, 2026 | $34.02 | $34.125 | $31.37 | $32.90 | 1.64M |
| Sep 23, 2026 | $34.85 | $35.09 | $34.09 | $34.19 | 752.48K |
| Sep 22, 2026 | $34.19 | $35.36 | $33.875 | $34.97 | 1.17M |
The latest Smart Investors Daily articles mentioning AGIO.
Company
Market Activity
Research & News
AGIO research
Company profile and research snapshot.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Truist Securities | Buy | — |
| Sep 21, 2026 | B of A Securities | Buy | — |
| Aug 7, 2026 | JP Morgan | Neutral | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 19, 2026
Investors are set to turn their focus on FDA decisions on experimental treatments for hepatitis B, RRP, sickle cell disease and psoriatic arthritis.
Yahoo · Oct 10, 2026
Agios Pharmaceuticals (AGIO) has set November 5, 2026, for a conference call and webcast covering third quarter results and business updates, giving investors a scheduled checkpoint on this rare disease focused biotech company. Against that backdrop, Agios Pharmaceuticals trades at US$31.81, with the share price down 8.14% over the past month and 22.85% over 90 days. The year to date share price return of 17.03% contrasts with a 1 year total shareholder return that has declined 21.67%. This...
Yahoo · Oct 9, 2026
Agios Pharmaceuticals has delivered a 37.6% gain over the past 3 years. The key question now is whether that share price aligns with the sales the business is generating. For anyone looking at Agios, the focus is less on recent swings and more on what its current market value suggests about the revenue power behind the ticker. A 37.6% return over 3 years puts meaningful weight on whether the market is paying a sensible price for Agios Pharmaceuticals relative to its sales base. For a biotech...
Yahoo · Oct 8, 2026
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m. ET to report its third quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGIO.
